TAVEGYL

This brand name is authorized in Ecuador, Estonia, Germany, Japan, Lithuania, Netherlands, Turkey.

Active ingredients

The drug TAVEGYL contains one active pharmaceutical ingredient (API):

1	Clemastine UNII 19259EGQ3D - CLEMASTINE FUMARATE
	Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action.
	Read more about Clemastine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AA04	Clemastine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AA Aminoalkyl ethers
Discover more medicines within R06AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	15607972, 15621386
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.954-09-04
EE	Ravimiamet	1006333, 1006366, 1160761
JP	医薬品医療機器総合機構	4419008B1073, 4419008B2070, 4419008F1431, 4419008Q1157
LT	Valstybinė vaistų kontrolės tarnyba	1007827, 1007828, 1088248
NL	Z-Index G-Standaard	14084805
NL	Z-Index G-Standaard, PRK	507, 7560
TR	İlaç ve Tıbbi Cihaz Kurumu	8681291010378, 8681291570384